Cambridge Healthtech Institute’s 5th Annual

Biophysical Approaches for Drug Discovery

Lead Generation Methods against PPIs, GPCRs, and Other Difficult Targets

April 17, 2020



This symposium convenes medicinal and biophysical chemists, computational chemists, and structural biologists to discuss advances in biophysical methods in drug discovery. An emphasis will be on case studies that highlight integration of various biophysical techniques for new drug lead generation. We will also cover applying biosensor-based screens to more ‘difficult’ target classes, such as protein-protein interactions (PPIs) and G protein-coupled receptors (GPCRs) or other complex membrane proteins, where traditional high-throughput screens are not ideal because of the absence of an enzymatic assay or physiologically relevant parameters.


Preliminary Agenda

NEW APPLICATIONS OF BIOPHYSICAL TECHNIQUES

Meeting the Challenges of Increasingly Diverse Chemical Matter using Label-free Biosensing

John Quinn, PhD, Director, Biochemistry & Cellular Pharmacology, Genentech

Biophysical Techniques to Identify Aggregating Compounds and Select Hits

Samantha Allen, PhD, Principal Scientist, Discovery Sciences, Janssen R&D LLC

Enabling Drug Discovery with Crude Reaction Mixture Screening

Ben Davis, PhD, Research Fellow, Vernalis Research

Development of Novel Thermo FRET- and BRET-Based Thermostability Assays

Dmitry Veprintsev, PhD, Professor, Molecular and Cellular Pharmacology, University of Nottingham

Determining Affinity from Irreversible Thermal Shifts

Justin Hall, PhD, Principal Scientist, Structural Biology & Biophysics, Pfizer

Biophysical Studies of Human GPCR Allosteric Modulators

Matthew Eddy, PhD, Assistant Professor, Chemistry, University of Florida

LEAD-GENERATION CASE STUDIES

Application of Biophysical Tools in Lead Identifications, Validations, and Optimizations: Case Studies and Lessons Learned

Anup Upadhyay, PhD, Senior Scientist III, Drug Discovery Science & Technology, AbbVie

Apolipoprotein A Drug Leads via Integrating Orthogonal Biophysical Techniques

Jenny Sandmark, PhD, Associate Principal Scientist, Drug Discovery, AstraZeneca

* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Japanese
Traditional Chinese
Simplified Chinese
Korean


Update History
2019/11/25
Sponsor updated
2019/10/31
Agenda,Sponsor updated